Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 6, 2026, 4:14 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–120 of 460 matching trials from the live ClinicalTrials.gov search.
Conditions
Sars-CoV-2 Infection
Interventions
Peginterferon lambda alfa-1a subcutaneous injection, Saline
Drug · Other
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 80 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Baltimore, Maryland
Recruiting Not applicable Interventional Accepts healthy volunteers

Obesity, Insulin Resistance, and PASC: Persistent SARS-CoV-2

NCT05833217
Conditions
Long COVID, Insulin Resistance, Insulin Sensitivity
Interventions
Adipose Tissue Biopsy, Steady State Plasma Glucose (SSPG) Test
Procedure · Diagnostic Test
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 80 Years
Enrollment
55 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
2
States / cities
Palo Alto, California
Conditions
COVID-19, Corona Virus Infection
Interventions
Pfizer-BioNTech mRNA COVID-19 vaccine, Moderna mRNA COVID-19 vaccine
Biological
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
137 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Ann Arbor, Michigan
Conditions
Thrombopenia, Covid19
Interventions
EP-7041 Injection
Drug
Lead sponsor
eXIthera Pharmaceuticals
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Los Angeles, California
Conditions
Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm, Symptomatic COVID-19 Infection Laboratory-Confirmed
Interventions
SARS-CoV-2 Antigen-specific Cytotoxic T-lymphocytes
Biological
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Houston, Texas
Terminated Phase 3 Interventional Results available

Colchicine Coronavirus SARS-CoV2 Trial (COLCORONA)

NCT04322682
Conditions
Corona Virus Infection
Interventions
Colchicine, Placebo oral tablet
Drug
Lead sponsor
Montreal Heart Institute
Other
Eligibility
40 Years and older
Enrollment
4,506 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
16
States / cities
Phoenix, Arizona • Yuma, Arizona • Bakersfield, California + 12 more
Completed Phase 2 Interventional Results available

SPI-1005 Treatment in Severe COVID-19 Patients

NCT04483973
Conditions
Covid19, Coronavirus, Coronavirus Infection, Corona Virus Infection
Interventions
Ebselen, Placebo
Drug
Lead sponsor
Sound Pharmaceuticals, Incorporated
Industry
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
7
States / cities
New Haven, Connecticut • Boise, Idaho • Kansas City, Kansas + 4 more
Recruiting Early Phase 1 Interventional Accepts healthy volunteers

Multiparametric [18F]F-AraG Imaging in Post-Acute Sequelae of COVID-19 (PASC)

NCT07076862
Conditions
PASC Post Acute Sequelae of COVID-19
Interventions
A.1 - [¹⁸F]F-AraG PET/CT (90-min dynamic + 4-h static), A.2 - [¹⁸F]F-AraG PET/CT (60-min dynamic only), B.1 - [¹⁸F]F-AraG PET/CT (90-min dynamic + 4-h static), B.2 - [¹⁸F]F-AraG PET/CT (60-min dynamic only)
Drug
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years and older
Enrollment
51 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2029
U.S. locations
2
States / cities
Sacramento, California • San Francisco, California
Conditions
Anosmia, Covid19, Ageusia, Hyposmia, Hypogeusia, SARS-CoV-2 Infection, COVID-19 Pandemic
Interventions
Smell Training
Behavioral
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 70 Years
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
St Louis, Missouri
Conditions
Coronavirus Infection, Severe Acute Respiratory Infection, Severe Acute Respiratory Syndrome Coronavirus 2
Interventions
Drug: NA-831, NA-831 and Atazanavir, NA-831and Dexamethasone, Atazanavir and Dexamethasone
Drug · Combination Product
Lead sponsor
Biomed Industries, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
525 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
31
States / cities
Los Angeles, California • Orange, California • Palo Alto, California + 27 more
Terminated Phase 1Phase 2 Interventional

RAPA-501-Allo Therapy of COVID-19-ARDS

NCT04482699
Conditions
Severe COVID-19 Disease
Interventions
RAPA-501-Allo off-the-shelf Therapy of COVID-19, Placebo
Biological · Other
Lead sponsor
Rapa Therapeutics LLC
Industry
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Hackensack, New Jersey
Conditions
SARS-CoV-2, COVID-19
Interventions
Sample collection
Other
Lead sponsor
COVID-19 Prevention Network
Network
Eligibility
18 Years and older
Enrollment
953 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
15
States / cities
Birmingham, Alabama • San Francisco, California • Miami, Florida + 11 more
Completed No phase listed Observational Accepts healthy volunteers

Long-Term Experience and Health Effects of COVID-19

NCT04477902
Conditions
Covid19, Corona Virus Infection, Quality of Life, Risk Reduction
Interventions
none - observational
Other
Lead sponsor
Altura
Industry
Eligibility
18 Years to 100 Years
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Mission Viejo, California
Conditions
Severe Acute Respiratory Syndrome - CoronaVirus 2 (SARS-CoV-2)
Interventions
Not listed
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
1,007 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Chicago, Illinois
Completed Phase 4 Interventional Accepts healthy volunteers Results available

SARS-CoV-2 Immune Responses After COVID-19 Therapy and Subsequent Vaccine

NCT04952402
Conditions
Covid19, SARS-CoV2 Infection
Interventions
Study-provided Moderna mRNA-1273 COVID-19 vaccine, Community-provided Moderna mRNA-1273 COVID-19 Vaccine, Community-Provided Pfizer-BioNTech BNT162b2 COVID-19 Vaccine
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
6
States / cities
Los Angeles, California • San Diego, California • Chicago, Illinois + 3 more
Conditions
COVID-19, Corona Virus Infection, Coronavirus-19, Sars-CoV2
Interventions
Hydroxychloroquine, Azithromycin, Vitamin C, Vitamin D, Zinc
Drug · Dietary Supplement
Lead sponsor
ProgenaBiome
Other
Eligibility
18 Years and older
Enrollment
118 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Ventura, California
Conditions
Coronavirus Infection
Interventions
Hydroxychloroquine Sulfate, Azithromycin, Chloroquine Sulfate
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
2
States / cities
St Louis, Missouri
Conditions
Respiratory Failure, ARDS
Interventions
Marker Therapeutics D2000 Cartridge (D2000) for use with the Spectra Optia® Apheresis System (Optia SPD Protocol)
Device
Lead sponsor
Marker Therapeutics AG
Industry
Eligibility
18 Years and older
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
7
States / cities
Little Rock, Arkansas • Albuquerque, New Mexico • Portland, Oregon + 4 more
Conditions
Ebola Virus Disease, Marburg Virus Disease
Interventions
cAd3-Marburg, cAd3-EBO-S
Biological
Lead sponsor
Albert B. Sabin Vaccine Institute
Other
Eligibility
18 Years to 50 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Conditions
COVID-19, SARS-CoV-2
Interventions
AZD5156 (Parent study Sentinel Safety Cohort), Placebo (Parent study Sentinel Safety Cohort), EVUSHELD™ (Parent study Main Cohort), AZD3152 (Parent study Main Cohort), Placebo (Parent study Main Cohort), AZD3152 (Sub-study), AZD7442 - EVUSHELD™ (Sub-study), AZD7442 (EVUSHELD™) (Sub-study) Immunocompromised participants offered AZD3152
Biological
Lead sponsor
AstraZeneca
Industry
Eligibility
12 Years to 130 Years
Enrollment
3,882 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
130
States / cities
Birmingham, Alabama • Mobile, Alabama • Glendale, Arizona + 108 more
Conditions
COVID-19, SARS-CoV-2 Infection
Interventions
Sampling
Diagnostic Test
Lead sponsor
INanoBio Inc.
Industry
Eligibility
18 Years and older
Enrollment
80 participants
Timeline
2020 – 2022
U.S. locations
1
States / cities
Tucson, Arizona
Conditions
SARS-CoV-2 Infection, COVID-19, Coronavirus Infection, SARS (Severe Acute Respiratory Syndrome)
Interventions
Not listed
Lead sponsor
University of Washington
Other
Eligibility
10 Years and older
Enrollment
155 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Seattle, Washington
Completed Not applicable Interventional

Fatigability in Long COVID-19

NCT05699538
Conditions
Long COVID
Interventions
Minimal-Dose Home-Based Resistance Exercise
Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
50 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Washington D.C., District of Columbia